Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cancer Discov. 2018 Oct 1;8(12):1632–1653. doi: 10.1158/2159-8290.CD-18-0657

Figure 1. Tet2 deletion in hematopoietic cells induces GC hyperplasia.

Figure 1.

A, Representative flow cytometry plot and quantification of (B220+CD95+GL7+) GC B-cells from Vav-Cre/Tet2+/+ (n=5) and Vav-Cre/Tet2−/− (n=5) mice at day 10 after immunization with SRBC. B, Quantification of flow cytometry data corresponding to total B cells (B220+), mature B cells (B220+IgD+IgM+), transitional B cells (B220+IgDintIgM+), follicular B cells (B220+CD23+CD21+), marginal zone B cells (B220+CD23lowCD21+) and plasmablasts/PC (CD138+) in the spleens of Vav-Cre/Tet2+/+ and Vav-Cre/Tet2−/− mice. C, Representative histologic sections of formalin-fixed, paraffin-embedded spleens from Vav-Cre/Tet2+/+ and Vav-Cre/Tet2−/− mice. Sections were stained with H&E and antibodies specific for B220, PNA and Ki-67. D, E, Quantification of GC area (D) and number of GCs (E) in the spleens of Vav-Cre/Tet2+/+ and Vav-Cre/Tet2−/− mice. two-tailed t test, ***p<0.001 ****p<0.0001.